Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $310

Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on AbbVie (NYSE: ABBV) and increased the price target from $296 to $310. This adjustment reflects a positive outlook for the company's performance in the market.